Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.
Dastan F, Saffaei A, Haseli S, Marjani M, Moniri A, Abtahian Z, Abedini A, Kiani A, Seifi S, Jammati H, Hashemian SMR, Pourabdollah Toutkaboni M, Eslaminejad A, Heshmatnia J, Sadeghi M, Nadji SA, Dastan A, Baghaei P, Varahram M, Yousefian S, Salamzadeh J, Tabarsi P. Dastan F, et al. Among authors: eslaminejad a. Int Immunopharmacol. 2020 Nov;88:106869. doi: 10.1016/j.intimp.2020.106869. Epub 2020 Aug 4. Int Immunopharmacol. 2020. PMID: 32889241 Free PMC article. Clinical Trial.
Clinical Manifestations of Patients with Coronavirus Disease 2019 (COVID-19) in a Referral Center in Iran.
Baghaei P, Nadji SA, Marjani M, Moniri A, Hashemian SM, Sheikhzade H, Abtahian Z, Heshmatnia J, Abedini A, Jamaati H, Mansourafshar B, Ahmadi ZH, Mokhber Dezfuli M, Seifi S, Sadeghi M, Mirenayat MS, Yassari F, Lookzadeh S, Farzanegan B, Kiani A, Vasheghani M, Dastan F, Eslaminejad A, Malekmohammad M, Varahram M, Zali A, Tabarsi P, Velayati AA. Baghaei P, et al. Among authors: eslaminejad a. Tanaffos. 2020 Nov;19(2):122-128. Tanaffos. 2020. PMID: 33262799 Free PMC article.
Favipiravir Effects on the Control of Clinical Symptoms of Hospitalized COVID-19 Cases: An Experience with Iranian Formulated Dosage Form.
Tabarsi P, Vahidi H, Saffaei A, Hashemian SMR, Jammati H, Daraei B, Mahboubi A, Kobarfard F, Marjani M, Moniri A, Abtahian Z, Abedini A, Eslaminejad A, Heshmatnia J, Mirenayat MS, Fakharian A, Seifi S, Sadeghi M, Dastan A, Haseli S, Nadji SA, Eskandari R, Yousefian S, Varahram M, Zali A, Velayati AA, Dastan F. Tabarsi P, et al. Among authors: eslaminejad a. Iran J Pharm Res. 2021 Fall;20(4):1-8. doi: 10.22037/ijpr.2021.115510.15401. Iran J Pharm Res. 2021. PMID: 35194422 Free PMC article.
National Research Institute of Tuberculosis and Lung Disease (NRITLD) Protocol for the Treatment of Patients with COVID-19.
Mirenayat MS, Abedini A, Kiani A, Eslaminejad A, Adimi Naghan P, Malekmohammad M, Heshmatnia J, Nadji SA, Idani E, Zahiri R, Lookzadeh S, Sheikhzade H, Dastan F, Porabdollah Toutkaboni M, Rezaei MS, Askari E, Tabarsi P, Marjani M, Moniri A, Hashemian SMR, Farzanegan B, Abtahian Z, Yassari F, Mansouri N, Mansouri D, Vasheghani M, Mansourafshar B, Mokhber Dezfoli M, Soleimani S, Seifi S, Naghashzadeh F, Fakharian A, Varahram M, Jamaati H, Zali A, Velayati AA. Mirenayat MS, et al. Among authors: eslaminejad a. Iran J Pharm Res. 2022 Mar 30;21(1):e123947. doi: 10.5812/ijpr.123947. eCollection 2022 Dec. Iran J Pharm Res. 2022. PMID: 35765502 Free PMC article.
NRITLD Protocol for the Management of Patients with COVID-19 Admitted to Hospitals.
Marjani M, Tabarsi P, Moniri A, Hashemian SM, Nadji SA, Abtahian Z, Malekmohammad M, Kiani A, Farzanegan B, Eslaminejad A, Fakharian A, Heshmatnia J, Abedini A, Seifi S, Yassari F, Mirenayat MS, Rezaei M, Sheikhzade H, Ahmadi ZH, Dastan F, Sadeghi M, Lookzadeh S, Porabdollah M, Askari E, Baghaei P, Mansourafshar B, Jahangirifard A, Vasheghani M, Mokhber Dezfuli M, Varahram M, Jamaati H, Mansouri D, Zali A, Velayati AA. Marjani M, et al. Among authors: eslaminejad a. Tanaffos. 2020 Nov;19(2):91-99. Tanaffos. 2020. PMID: 33262795 Free PMC article. Review. No abstract available.
Combination therapy of IFNβ1 with lopinavir-ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients.
Baghaei P, Dastan F, Marjani M, Moniri A, Abtahian Z, Ghadimi S, Valizadeh M, Heshmatnia J, Sadat Mirenayat M, Abedini A, Kiani A, Eslaminejad A, MohammadReza Hashemian S, Jamaati H, Zali A, Akbar Velayati A, Tabarsi P. Baghaei P, et al. Among authors: eslaminejad a. Int Immunopharmacol. 2021 Mar;92:107329. doi: 10.1016/j.intimp.2020.107329. Epub 2020 Dec 26. Int Immunopharmacol. 2021. PMID: 33412395 Free PMC article.
34 results